Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPARγ (peroxisome proliferator-activated receptor γ) and RUNX2 (runt-related transcription factor 2).

Samankaltaisia teoksia

• Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2)
  Tekijä: Stechschulte, Lance A., et al.
  Julkaistu: (2016)
• Reciprocal regulation of PPARγ and RUNX2 activities in marrow mesenchymal stem cells: Fine balance between p38 MAPK and Protein Phosphatase 5
  Tekijä: Stechschulte, Lance A., et al.
  Julkaistu: (2017)
• Reciprocal Control of Osteogenic and Adipogenic Differentiation by ERK/MAP Kinase Phosphorylation of Runx2 and PPARγ Transcription Factors
  Tekijä: GE, CHUNXI, et al.
  Julkaistu: (2016)
• FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone
  Tekijä: Stechschulte, Lance A., et al.
  Julkaistu: (2016)
• PPARs and Bone Metabolism
  Tekijä: Lecka-Czernik, Beata
  Julkaistu: (2006)